文献速递肿瘤 PET/CT

[18F]FDG PET/CT评估儿童肉瘤新辅助化疗早期反应的前瞻性单中心试验

[18F]FDG PET/CT for evaluating early response to neoadjuvant chemotherapy in pediatric patients with sarcoma: a prospective single-center trial.
PubMed 文献 · EJNMMI Res · 2020-10-15

该前瞻性单中心试验纳入34例骨或软组织肉瘤儿童患者,在新辅助化疗前(PET1)和开始后6周(PET2)行[18F]FDG PET/CT,评估PET参数对总生存(OS)、进展时间(TTP)及病理/MRI反应预测价值。结果显示PET2参数与较长TTP相关(p<0.02),ΔMTV与组织学反应相关(p=0.047),但PET1、PET2及ΔPET参数均与OS无关。

要点

  • 新辅助化疗开始后6周的[18F]FDG PET/CT参数与进展时间相关(p<0.02)。
  • ΔMTV与新辅助化疗的组织学反应相关(p=0.047)。
  • PET1、PET2及ΔPET参数均未显示与总生存相关。

核心结论

  • 新辅助化疗开始后6周行[18F]FDG PET/CT可作为儿童肉瘤进展时间和病理反应的早期中期生物标志物,但不能预测总生存。

研究设计与样本

  • 前瞻性单中心试验纳入34例骨或软组织肉瘤儿童患者(10例女性,24例男性,中位年龄15.1岁),在新辅助化疗前4周内行PET1、开始后6周行PET2,获取SUVmax、SUVmean、SUVpeak、MTV和TLG及其变化(ΔPET),主要终点为PET参数对OS和TTP的预测价值,次要终点为预测病理或MRI评估的化疗反应。

主要发现

  • 17/34例(50%)为骨肉瘤,13/34例(38%)为尤文肉瘤,2/34例(6%)为滑膜肉瘤,2/34例(6%)为胚胎性肝肉瘤;中位随访39个月(范围16-84)。
  • 8/34例(24%)死亡,9/34例(27%)带病生存,17/34例(50%)无残留/复发疾病证据。
  • 15/34例(44%)为反应者,19/34例(56%)为非反应者。
  • PET2参数与较长TTP相关(p<0.02)。
  • ΔMTV与新辅助化疗的组织反应相关(p=0.047)。

关键数值与推荐

  • PET2参数与较长TTP相关(p<0.02)。
  • ΔMTV与新辅助化疗组织反应相关(p=0.047)。
  • PET1、PET2或ΔPET参数均与OS无关。

临床怎么用

  • 对新辅助化疗的儿童肉瘤患者,可在化疗开始后6周行[18F]FDG PET/CT,利用PET2参数和ΔMTV早期评估进展风险与病理反应。
  • 不应仅依据PET1、PET2或ΔPET参数判断总生存预后。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: This is a prospective, single-center trial in pediatric patients with sarcoma aiming to evaluate [18F]FDG PET/CT as a tool for early response assessment to neoadjuvant chemotherapy (neo-CTX). METHODS: Bone or soft tissue sarcoma patients with (1) baseline [18F]FDG PET/CT within 4 weeks prior to the start of neo-CTX (PET1), (2) early interim [18F]FDG PET/CT (6 weeks after the start of neo-CTX (PET2), (3) evaluation of neo-CTX response by histology or MRI, and (4) definitive therapy after neo-CTX (surgery or radiation) were included. Semiquantitative PET parameters (SUVmax, SUVmean, SUVpeak, MTV and TLG) and their changes from PET1 to PET2 (ΔPET) were obtained. The primary endpoint was to evaluate the predictive value of PET1, PET2 and ΔPET parameters for overall survival (OS) and time to progression (TTP). The secondary outcome was to evaluate if [18F]FDG PET/CT can predict the response to neo-CTX assessed by histopathology or MRI. Primary and secondary outcomes were also evaluated in a subpopulation of patients with bone involvement only. RESULTS: Thirty-four consecutive patients were enrolled (10 females; 24 males; median age 15.1 years). 17/34 patients (50%) had osteosarcoma, 13/34 (38%) Ewing's sarcoma, 2/34 (6%) synovial sarcoma and 2/34 (6%) embryonal liver sarcoma. Median follow-up was 39 months (range 16-84). Eight of 34 patients (24%) died, 9/34 (27%) were alive with disease, and 17/34 (50%) had no evidence of residual/recurrent disease. Fifteen of 34 (44%) and 19/34 (56%) were responders and non-responders, respectively. PET2-parameters were associated with longer TTP (p < 0.02). ΔMTV was associated with tissue response to neo-CTX (p = 0.047). None of the PET1, PET2 or ΔPET parameters were associated with OS. CONCLUSION: [18F]FDG PET/CT performed 6 weeks after the start of neo-CTX can serve as an early interim biomarker for TTP and pathologic response but not for OS in pediatric patients with sarcoma.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Polverari G, Ceci F, Passera R, et al. [18F]FDG PET/CT for evaluating early response to neoadjuvant chemotherapy in pediatric patients with sarcoma: a prospective single-center trial. EJNMMI Res. 2020. PMID: 33063147. doi:10.1186/s13550-020-00715-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。